Skip to content
← Full study record

NCT01871727 · OUTCOME

Lead-In Part: Time to Reach Maximum (Peak) Concentration After Drug Administration (Tmax)

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma · Source last updated 2024-11-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
minute
Interval / dispersion
Full Range
Time frame
Cycles 1, 3, 5 Day 1: Pre-dose up to 300 hours post-dose (Cycle length was 21 days)

What was measured

Participants were not available for analysis in 15 mcg/kg (Cycles 3 and 5), 6 mcg/kg (Cycle 5), 9 mcg/kg (Cycles 3 and 5), 12 mcg/kg (Cycle 3), hence no PK data was collected and analyzed for these doses and cycles.

Analysis population: Lead-in PK analysis set included all participants who received at least one dose of study drug and from whom at least one valid E7777 PK parameter was obtained. Here "overall number of participants analyzed" signifies participants who were evaluable for this outcome measure. Here "number analyzed" signifies participants who were evaluable for this outcome measure for given timepoints.

Groups in this outcome

Lead-In Part: E7777 6 mcg/kg

Participants were treated with E7777 6 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.

Lead-In Part: E7777 9 mcg/kg

Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minute on 5 consecutive days during every 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-In Part.

Lead-In Part: E7777 12 mcg/kg

Participants were treated with E7777 12 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.

Lead-In Part: E7777 15 mcg/kg

Participants were treated with E7777 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lead-In Part: E7777 6 mcg/kg2
Lead-In Part: E7777 9 mcg/kg7
Lead-In Part: E7777 12 mcg/kg8
Lead-In Part: E7777 15 mcg/kg2

Reported measurements

Cycle 1 Day 1

Analysis denominator · Participants

GroupSource count
Lead-In Part: E7777 6 mcg/kg2
Lead-In Part: E7777 9 mcg/kg7
Lead-In Part: E7777 12 mcg/kg8
Lead-In Part: E7777 15 mcg/kg2
Values in minute · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Lead-In Part: E7777 6 mcg/kg75Not reported6090Not reported
Lead-In Part: E7777 9 mcg/kg60Not reported30180Not reported
Lead-In Part: E7777 12 mcg/kg61.5Not reported49.290Not reported
Lead-In Part: E7777 15 mcg/kg60Not reported6060Not reported
Cycle 3 Day 1

Analysis denominator · Participants

GroupSource count
Lead-In Part: E7777 6 mcg/kg1
Lead-In Part: E7777 9 mcg/kg0
Lead-In Part: E7777 12 mcg/kg0
Lead-In Part: E7777 15 mcg/kg0
Values in minute · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Lead-In Part: E7777 6 mcg/kg60Not reported6060Not reported
Cycle 5 Day 1

Analysis denominator · Participants

GroupSource count
Lead-In Part: E7777 6 mcg/kg0
Lead-In Part: E7777 9 mcg/kg0
Lead-In Part: E7777 12 mcg/kg1
Lead-In Part: E7777 15 mcg/kg0
Values in minute · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Lead-In Part: E7777 12 mcg/kg60Not reported6060Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        60
        upper Limit
        90
        value
        75
      2. group Id
        OG001
        lower Limit
        30
        upper Limit
        180
        value
        60
      3. group Id
        OG002
        lower Limit
        49.2
        upper Limit
        90
        value
        61.5
      4. group Id
        OG003
        lower Limit
        60
        upper Limit
        60
        value
        60
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        7
      3. group Id
        OG002
        value
        8
      4. group Id
        OG003
        value
        2
      units
      Participants
    title
    Cycle 1 Day 1
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        60
        upper Limit
        60
        value
        60
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      units
      Participants
    title
    Cycle 3 Day 1
  3. categories
    1. measurements
      1. group Id
        OG002
        lower Limit
        60
        upper Limit
        60
        value
        60
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        0
      units
      Participants
    title
    Cycle 5 Day 1
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    2. group Id
      OG001
      value
      7
    3. group Id
      OG002
      value
      8
    4. group Id
      OG003
      value
      2
    units
    Participants
description
Participants were not available for analysis in 15 mcg/kg (Cycles 3 and 5), 6 mcg/kg (Cycle 5), 9 mcg/kg (Cycles 3 and 5), 12 mcg/kg (Cycle 3), hence no PK data was collected and analyzed for these doses and cycles.
dispersion Type
Full Range
groups
  1. description
    Participants were treated with E7777 6 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.
    id
    OG000
    title
    Lead-In Part: E7777 6 mcg/kg
  2. description
    Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minute on 5 consecutive days during every 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-In Part.
    id
    OG001
    title
    Lead-In Part: E7777 9 mcg/kg
  3. description
    Participants were treated with E7777 12 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.
    id
    OG002
    title
    Lead-In Part: E7777 12 mcg/kg
  4. description
    Participants were treated with E7777 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.
    id
    OG003
    title
    Lead-In Part: E7777 15 mcg/kg
param Type
MEDIAN
population Description
Lead-in PK analysis set included all participants who received at least one dose of study drug and from whom at least one valid E7777 PK parameter was obtained. Here "overall number of participants analyzed" signifies participants who were evaluable for this outcome measure. Here "number analyzed" signifies participants who were evaluable for this outcome measure for given timepoints.
reporting Status
POSTED
time Frame
Cycles 1, 3, 5 Day 1: Pre-dose up to 300 hours post-dose (Cycle length was 21 days)
title
Lead-In Part: Time to Reach Maximum (Peak) Concentration After Drug Administration (Tmax)
type
SECONDARY
unit Of Measure
minute

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice